Who is sponsoring NCT00408616?

NCT00408616 is sponsored by ALK-Abelló A/S.

What drugs are being tested in NCT00408616?

Interventions: Grazax-R, Grazax Placebo.

What is the status of NCT00408616?

NCT00408616 is currently COMPLETED.

Last reviewed 2009-03-06 · How we verify

A Phase III Trial Investigating the Efficacy and Safety of Grazax in Children Aged 5-16 Years With Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma

NCT00408616 Phase 3 COMPLETED

The purpose of this study is to investigate if immunotherapy with Grazax is safe and reduces the hayfever symptoms and the use of symptom relieving medications in children during the grass pollen season

Details

Lead sponsor	ALK-Abelló A/S
Phase	Phase 3
Status	COMPLETED
Enrolment	253
Start date	2006-11
Completion	2007-11

Conditions

Allergy

Interventions

Grazax-R
Grazax Placebo

Primary outcomes

Hayfever symptoms — Grass pollen season 2007
Intake of hayfever symptom relieving medication — Grass pollen season 2007

Countries

Germany